Cyberonics Expects VNS Will Capture 4% Of U.S. Depression Market By 2010
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics anticipates FDA approval of a depression indication for its VNS Therapy vagus nerve stimulation system by October 2004
You may also be interested in...
Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel
FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md
Alzheimer’s May Be Cyberonics’ New Frontier; Trial Costs Projected
Future indications for Cyberonics' vagus nerve stimulation therapy may include Alzheimer's disease, chronic migraines and anxiety, although a decision on which to pursue first in pivotal trials awaits FDA approval for depression, the firm says
Cyberonics’ VNS Therapy Approvable As Last-Resort Depression Fix – Panel
FDA's Neurological Devices Panel set aside its desire for an additional, randomized trial of Cyberonics' VNS Therapy depression indication at a June 15 meeting to review the device in Gaithersburg, Md